Iovance Biotherapeutics, Inc. (IOVA)
USD 2.8
(-6.83%)
USD 2.8
(-6.83%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 450.99 Million USD | 7.46% |
| 2022 | 398.87 Million USD | 16.39% |
| 2021 | 342.7 Million USD | 30.83% |
| 2020 | 261.93 Million USD | 26.62% |
| 2019 | 206.87 Million USD | 61.29% |
| 2018 | 128.25 Million USD | 38.09% |
| 2017 | 92.87 Million USD | 73.15% |
| 2016 | 53.63 Million USD | 92.53% |
| 2015 | 27.86 Million USD | 131.39% |
| 2014 | 12.04 Million USD | -46.82% |
| 2013 | 22.64 Million USD | 178.4% |
| 2012 | 8.13 Million USD | -61.38% |
| 2011 | 21.05 Million USD | 2482.53% |
| 2010 | 815.41 Thousand USD | 5070.0% |
| 2009 | 15.77 Thousand USD | -72.4% |
| 2008 | 57.14 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 105.9 Million USD | -1.63% |
| 2024 Q2 | 96.27 Million USD | -9.09% |
| 2023 Q3 | 114.49 Million USD | 5.74% |
| 2023 FY | 428.62 Million USD | 7.46% |
| 2023 Q1 | 110.85 Million USD | 3.57% |
| 2023 Q2 | 108.27 Million USD | -2.33% |
| 2023 Q4 | 107.65 Million USD | -5.97% |
| 2022 Q3 | 100.39 Million USD | 0.66% |
| 2022 FY | 398.87 Million USD | 16.39% |
| 2022 Q1 | 91.71 Million USD | -7.79% |
| 2022 Q2 | 99.73 Million USD | 8.75% |
| 2022 Q4 | 107.03 Million USD | 6.61% |
| 2021 Q3 | 86.24 Million USD | 5.91% |
| 2021 Q4 | 99.46 Million USD | 15.33% |
| 2021 FY | 342.7 Million USD | 30.83% |
| 2021 Q1 | 75.57 Million USD | 10.27% |
| 2021 Q2 | 81.42 Million USD | 7.75% |
| 2020 FY | 261.93 Million USD | 26.62% |
| 2020 Q4 | 68.53 Million USD | 16.23% |
| 2020 Q2 | 63.62 Million USD | -10.14% |
| 2020 Q1 | 70.81 Million USD | 8.75% |
| 2020 Q3 | 58.96 Million USD | -7.33% |
| 2019 Q3 | 51.61 Million USD | 2.88% |
| 2019 Q2 | 50.16 Million USD | 25.46% |
| 2019 Q4 | 65.11 Million USD | 26.16% |
| 2019 FY | 206.87 Million USD | 61.29% |
| 2019 Q1 | 39.98 Million USD | 14.43% |
| 2018 Q2 | 31.37 Million USD | 16.75% |
| 2018 FY | 128.25 Million USD | 38.09% |
| 2018 Q4 | 34.94 Million USD | -0.33% |
| 2018 Q3 | 35.06 Million USD | 11.73% |
| 2018 Q1 | 26.87 Million USD | 3.09% |
| 2017 FY | 92.87 Million USD | 73.15% |
| 2017 Q1 | 20.88 Million USD | 31.14% |
| 2017 Q2 | 23.58 Million USD | 12.93% |
| 2017 Q3 | 22.34 Million USD | -5.25% |
| 2017 Q4 | 26.07 Million USD | 16.69% |
| 2016 Q3 | 18.97 Million USD | 61.84% |
| 2016 Q2 | 11.72 Million USD | 67.29% |
| 2016 Q1 | 7.01 Million USD | -22.4% |
| 2016 Q4 | 15.92 Million USD | -16.1% |
| 2016 FY | 53.63 Million USD | 92.53% |
| 2015 FY | 27.86 Million USD | 131.39% |
| 2015 Q4 | 9.03 Million USD | 18.2% |
| 2015 Q3 | 7.64 Million USD | 18.68% |
| 2015 Q2 | 6.44 Million USD | 21.56% |
| 2015 Q1 | 5.29 Million USD | 8.83% |
| 2014 Q4 | 4.86 Million USD | 73.71% |
| 2014 Q3 | 2.8 Million USD | 32.81% |
| 2014 Q2 | 2.11 Million USD | -6.61% |
| 2014 Q1 | 2.25 Million USD | -80.35% |
| 2014 FY | 12.04 Million USD | -46.82% |
| 2013 Q1 | 704.91 Thousand USD | -59.08% |
| 2013 Q2 | 1.02 Million USD | 46.01% |
| 2013 Q3 | 9.4 Million USD | 814.16% |
| 2013 Q4 | 11.49 Million USD | 22.2% |
| 2013 FY | 22.64 Million USD | 178.4% |
| 2012 Q4 | 1.72 Million USD | 5.84% |
| 2012 Q3 | 1.62 Million USD | -1.14% |
| 2012 FY | 8.13 Million USD | -61.38% |
| 2012 Q2 | 1.64 Million USD | -47.5% |
| 2012 Q1 | 3.13 Million USD | -22.08% |
| 2011 Q4 | 4.02 Million USD | -30.78% |
| 2011 Q1 | 658.25 Thousand USD | 32.69% |
| 2011 Q2 | 10.56 Million USD | 1504.43% |
| 2011 Q3 | 5.81 Million USD | -44.95% |
| 2011 FY | 21.05 Million USD | 2482.53% |
| 2010 Q1 | 67.68 Thousand USD | 2786.14% |
| 2010 FY | 815.41 Thousand USD | 5070.0% |
| 2010 Q4 | 496.07 Thousand USD | 197.0% |
| 2010 Q3 | 167.02 Thousand USD | 97.36% |
| 2010 Q2 | 84.62 Thousand USD | 25.04% |
| 2009 Q1 | 6612.00 USD | -53.88% |
| 2009 Q2 | 3345.00 USD | -49.41% |
| 2009 Q3 | 3470.00 USD | 3.74% |
| 2009 Q4 | 2345.00 USD | -32.42% |
| 2009 FY | 15.77 Thousand USD | -72.4% |
| 2008 FY | 57.14 Thousand USD | 0.0% |
| 2008 Q4 | 14.33 Thousand USD | 480.25% |
| 2008 Q1 | 25.29 Thousand USD | 0.0% |
| 2008 Q2 | 15.03 Thousand USD | -40.56% |
| 2008 Q3 | 2471.00 USD | -83.57% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -63.859% |
| Alkermes plc | 996.24 Million USD | 54.731% |
| Agenus Inc. | 78.18 Million USD | -476.843% |
| Aptorum Group Limited | 10.56 Thousand USD | -4268241.851% |
| Ardelyx, Inc. | 169.93 Million USD | -165.388% |
| Dyadic International, Inc. | 9.15 Million USD | -4827.433% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -1926.662% |
| Lantern Pharma Inc. | 17.87 Million USD | -2422.675% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -6599.298% |
| Novavax, Inc. | 779.12 Million USD | 42.115% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -456.356% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -448.68% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -2222.49% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -1423.316% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -748.906% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -18.528% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1755.434% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -1090.929% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -1365.643% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -432.359% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -2483.451% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -167.753% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -1278.551% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -182.246% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 74.946% |
| AlloVir, Inc. | 180.93 Million USD | -149.26% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -1.179% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -1419.416% |
| Bicycle Therapeutics plc | 216.92 Million USD | -107.906% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -162.355% |
| ChromaDex Corporation | 56.37 Million USD | -699.931% |
| Chimerix, Inc. | 93.38 Million USD | -382.919% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -3142.305% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -199.591% |
| CRISPR Therapeutics AG | 463.49 Million USD | 2.697% |
| Precision BioSciences, Inc. | 92.46 Million USD | -387.755% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -77.526% |
| Fortress Biotech, Inc. | 200.19 Million USD | -125.277% |
| Fortress Biotech, Inc. | 200.19 Million USD | -125.277% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -1277.246% |
| ImmuCell Corporation | 9.61 Million USD | -4589.363% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -185.775% |
| Immix Biopharma, Inc. | 16.14 Million USD | -2694.064% |
| Incyte Corporation | 1.19 Billion USD | 62.117% |
| Innoviva, Inc. | 132.15 Million USD | -241.263% |
| IO Biotech, Inc. | 91.44 Million USD | -393.196% |
| Jaguar Health, Inc. | 42.01 Million USD | -973.409% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -166.423% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -434.84% |
| ContextLogic Inc. | 387 Million USD | -16.536% |
| MiMedx Group, Inc. | 229.72 Million USD | -96.317% |
| MEI Pharma, Inc. | 34.78 Million USD | -1196.516% |
| NextCure, Inc. | 67.63 Million USD | -566.784% |
| Onconetix, Inc. | 34.9 Million USD | -1191.969% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -3438.31% |
| Opthea Limited | 191.96 Million USD | -134.932% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -16290.299% |
| Vaxcyte, Inc. | 468.04 Million USD | 3.642% |
| PDS Biotechnology Corporation | 43.04 Million USD | -947.719% |
| Precigen, Inc. | 84.18 Million USD | -435.742% |
| Pharming Group N.V. | 225.49 Million USD | -100.005% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -168.725% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -521.494% |
| PureTech Health plc | 144.59 Million USD | -211.897% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -246.217% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -83.96% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -1755.434% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -97.216% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -1361.463% |
| Acelyrin, Inc. | 422.06 Million USD | -6.854% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -3497596.603% |
| Summit Therapeutics Inc. | 87.68 Million USD | -414.327% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -1116.795% |
| Senti Biosciences, Inc. | 94.7 Million USD | -376.208% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -265.02% |
| Elevation Oncology, Inc. | 45.44 Million USD | -892.393% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -1430.398% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -11340.576% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -241.209% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -1223.142% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -5236.564% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -148.754% |
| Seer, Inc. | 110.49 Million USD | -308.175% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -538.855% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -382.459% |
| ESSA Pharma Inc. | 32.13 Million USD | -1303.472% |
| GlycoMimetics, Inc. | 39.28 Million USD | -1047.994% |
| GT Biopharma, Inc. | 13.57 Million USD | -3221.987% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -105.155% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -124.246% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -73.843% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -694.575% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -733.937% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -4438.228% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -11.753% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -2282.551% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -789.655% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -73.687% |
| Aptose Biosciences Inc. | 52.35 Million USD | -761.397% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -3029.641% |
| Soligenix, Inc. | 7.79 Million USD | -5685.484% |
| Century Therapeutics, Inc. | 56.07 Million USD | -704.325% |
| Kura Oncology, Inc. | 165.8 Million USD | -172.004% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -293.856% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -5321.241% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -18073.191% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -318.757% |
| Autolus Therapeutics plc | 196.72 Million USD | -129.249% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -432.73% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -287.275% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -2226.745% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -40.165% |
| GRI Bio, Inc. | 11.33 Million USD | -3880.521% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -6291.895% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -243.763% |
| IGM Biosciences, Inc. | 265.59 Million USD | -69.807% |
| INmune Bio, Inc. | 29.89 Million USD | -1408.54% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -161.363% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1018.692% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2722.347% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -2764.984% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -626.26% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -319.443% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -63.585% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -49.607% |
| Verastem, Inc. | 92.08 Million USD | -389.763% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -2414.036% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -142.828% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -271.472% |
| Histogen Inc. | 14.27 Million USD | -3059.985% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -2710.251% |
| Surrozen, Inc. | 18.55 Million USD | -2331.229% |
| Organovo Holdings, Inc. | 14.91 Million USD | -2923.755% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8759.962% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -655.772% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -1658.463% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -859.437% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -5808.585% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -153.173% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -830.881% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -84.076% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -2834.896% |
| Apollomics, Inc. | 54.14 Million USD | -733.013% |
| Amarin Corporation plc | 272.35 Million USD | -65.589% |
| Mesoblast Limited | 5.9 Million USD | -7541.359% |
| Turnstone Biologics Corp. | 78.33 Million USD | -475.701% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -84.741% |
| Synaptogenix, Inc. | 8.31 Million USD | -5324.596% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -2991.958% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -78.219% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1253.111% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -5006.794% |
| Exelixis, Inc. | 1.58 Billion USD | 71.578% |
| Better Therapeutics, Inc. | 38.26 Million USD | -1078.697% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -94.352% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 47.265% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3719.688% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -5508.036% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -1403.661% |
| Gritstone bio, Inc. | 148.37 Million USD | -203.957% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -554.932% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -2656.644% |
| Avid Bioservices, Inc. | 25.99 Million USD | -1634.855% |
| Insmed Incorporated | 949.26 Million USD | 52.49% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -2774.437% |
| MediWound Ltd. | 18.86 Million USD | -2290.253% |
| OmniAb, Inc. | 83.89 Million USD | -437.568% |
| Alector, Inc. | 248.8 Million USD | -81.266% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -92.479% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -763.128% |
| Zai Lab Limited | 547.47 Million USD | 17.623% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -13.129% |
| Aura Biosciences, Inc. | 84.99 Million USD | -430.636% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -82.486% |
| Immunic, Inc. | 99.22 Million USD | -354.525% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -183.622% |
| Veracyte, Inc. | 357.93 Million USD | -25.999% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 94.998% |
| FibroGen, Inc. | 398.11 Million USD | -13.283% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3073.772% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -6447.568% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -6229.076% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 86.147% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -1643.103% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -42.474% |
| TG Therapeutics, Inc. | 198.47 Million USD | -127.229% |
| Galecto, Inc. | 35.62 Million USD | -1165.874% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -1008.39% |
| Fortrea Holdings Inc. | 457.3 Million USD | 1.379% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -730.895% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -1461.718% |
| XBiotech Inc. | 37.51 Million USD | -1102.327% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -554.932% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -2084.091% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -217.464% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -355.204% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -307.342% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 52.936% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -1463.505% |
| Vaxxinity, Inc. | 56.05 Million USD | -704.612% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -4.726% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -1921.637% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -306.787% |
| NexImmune, Inc. | 28.16 Million USD | -1501.111% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -8053.991% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -2420.569% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 83.981% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -1671.448% |
| Scopus BioPharma Inc. | 11.71 Million USD | -3749.746% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -254.939% |
| Ainos, Inc. | 12.95 Million USD | -3381.855% |
| Pluri Inc. | 22.48 Million USD | -1906.197% |
| Prothena Corporation plc | 282.4 Million USD | -59.697% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -125.472% |
| Celularity Inc. | 215.05 Million USD | -109.708% |
| Rallybio Corporation | 78.93 Million USD | -471.369% |
| Cue Biopharma, Inc. | 19.54 Million USD | -2207.814% |
| MeiraGTx Holdings plc | 151.07 Million USD | -198.517% |
| Omeros Corporation | 94.75 Million USD | -375.977% |
| Humacyte, Inc. | 23.49 Million USD | -1819.364% |
| Immunocore Holdings plc | 308.04 Million USD | -46.407% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -13203.628% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -419.188% |
| Blueprint Medicines Corporation | 722.86 Million USD | 37.61% |
| CalciMedica, Inc. | 21.81 Million USD | -1967.163% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -504.062% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -180.923% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -163.284% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -52.91% |
| Pulmatrix, Inc. | 22.03 Million USD | -1946.433% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -1204.39% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -407.498% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 18.234% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -521.622% |
| Cytokinetics, Incorporated | 173.61 Million USD | -159.771% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -1210.302% |
| Nutriband Inc. | 5.73 Million USD | -7765.2% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -934.079% |
| Vor Biopharma Inc. | 126.03 Million USD | -257.829% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 62.075% |
| Evogene Ltd. | 27.79 Million USD | -1522.861% |
| ProKidney Corp. | 151.52 Million USD | -197.642% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -508.012% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -5762.959% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 26.576% |
| CorMedix Inc. | 48.95 Million USD | -821.187% |
| BioLineRx Ltd. | 50.8 Million USD | -787.747% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -199.265% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -1084.579% |
| Atai Life Sciences N.V. | 125.78 Million USD | -258.543% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -452.421% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -453.984% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -78.574% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -1277.498% |
| MediciNova, Inc. | 10.9 Million USD | -4037.45% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -250.095% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -6112.432% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7388.875% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 5.325% |
| Biomea Fusion, Inc. | 126.13 Million USD | -257.548% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 65.621% |
| Mereo BioPharma Group plc | 35.84 Million USD | -1158.281% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -136.012% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -96.123% |
| Absci Corporation | 73.66 Million USD | -512.213% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1535.099% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -237.595% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -86.236% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -72.103% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -116.83% |
| Allakos Inc. | 196.05 Million USD | -130.033% |
| Imunon, Inc. | 20.31 Million USD | -2120.5% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -297.459% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -22.349% |
| BioAtla, Inc. | 129.68 Million USD | -247.755% |
| NLS Pharmaceutics AG | 11.8 Million USD | -3719.688% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -2746.639% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -431.092% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -980.016% |
| XOMA Corporation | 46.46 Million USD | -870.65% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -305.675% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -216.569% |
| aTyr Pharma, Inc. | 12.97 Million USD | -3374.79% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -335.086% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -160.886% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -77.024% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -1105.606% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -5383.322% |
| Akari Therapeutics, Plc | 16.8 Million USD | -2583.524% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -19732.847% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -50.674% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6602.498% |
| UroGen Pharma Ltd. | 138.88 Million USD | -224.717% |
| Sutro Biopharma, Inc. | 243 Million USD | -85.587% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -6099.539% |
| Orgenesis Inc. | 45.75 Million USD | -885.626% |
| Entera Bio Ltd. | 8.86 Million USD | -4990.214% |
| GH Research PLC | 41.22 Million USD | -994.059% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -1654.29% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -443.018% |
| Xencor, Inc. | 306.97 Million USD | -46.914% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -9041.245% |
| Replimune Group, Inc. | 234.77 Million USD | -92.097% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -2101.052% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -135.142% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -6602.498% |
| Portage Biotech Inc. | 18.19 Million USD | -2378.12% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -6112.432% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -329.677% |
| OncoCyte Corporation | 25.63 Million USD | -1659.149% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -7298.656% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -3836.376% |
| Purple Biotech Ltd. | -22.46 Million USD | 2107.357% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -2636.608% |
| scPharmaceuticals Inc. | 65.17 Million USD | -591.941% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -5235.468% |
| HilleVax, Inc. | 133.34 Million USD | -238.215% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -4284.959% |
| Tharimmune, Inc. | 9.45 Million USD | -4669.778% |
| Genprex, Inc. | 31.06 Million USD | -1351.979% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -140.496% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -1337.336% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -58853.333% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -8179.782% |
| OKYO Pharma Limited | 8243.57 USD | -5470745.762% |
| Savara Inc. | 15.74 Million USD | -2764.357% |
| Curis, Inc. | 58.35 Million USD | -672.844% |
| Daré Bioscience, Inc. | 33.6 Million USD | -1241.866% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -8756.044% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -5944.672% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -1568.985% |
| BeiGene, Ltd. | 3.28 Billion USD | 86.278% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -2161.83% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 9.578% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -193.516% |
| Erasca, Inc. | 141.52 Million USD | -218.667% |
| bluebird bio, Inc. | 240.23 Million USD | -87.732% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9862.35% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 74.174% |
| DBV Technologies S.A. | 92.16 Million USD | -389.359% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -9862.35% |
| Moderna, Inc. | 6.39 Billion USD | 92.947% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -958.445% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -3039.308% |
| Molecular Templates, Inc. | 63.09 Million USD | -614.829% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -576.141% |
| Travere Therapeutics, Inc. | 472 Million USD | 4.451% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -214.695% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -626.447% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -938.819% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -116.688% |
| MacroGenics, Inc. | 217.21 Million USD | -107.625% |
| RenovoRx, Inc. | 11.39 Million USD | -3857.468% |
| Adicet Bio, Inc. | 152.03 Million USD | -196.632% |
| Prime Medicine, Inc. | 186.63 Million USD | -141.639% |
| Aditxt, Inc. | 25.95 Million USD | -1637.879% |
| Adagene Inc. | 41.83 Million USD | -978.122% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -6069.452% |
| Quantum-Si incorporated | 111.65 Million USD | -303.902% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -162.434% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -2993.704% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -1158.983% |
| SciSparc Ltd. | 9.01 Million USD | -4904.916% |
| Vericel Corporation | 142.04 Million USD | -217.511% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -5109.778% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -1853.315% |
| Generation Bio Co. | 144.46 Million USD | -212.177% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -443.169% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -421.62% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -52.507% |
| Invivyd, Inc. | 205.75 Million USD | -119.189% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -524.999% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -4708.795% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -499.294% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -4284.106% |
| 2seventy bio, Inc. | 289.88 Million USD | -55.575% |
| ADMA Biologics, Inc. | 66.58 Million USD | -577.309% |
| Clene Inc. | 41.07 Million USD | -998.028% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -3421.213% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -723.04% |
| GeoVax Labs, Inc. | 6.02 Million USD | -7388.875% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -28.106% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -1127.793% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -1237.147% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -334.893% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -1283.881% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -164.857% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 41.256% |
| Evaxion Biotech A/S | 22.27 Million USD | -1925.115% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -232.728% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -92.008% |
| Trevena, Inc. | 38.41 Million USD | -1074.063% |
| Surrozen, Inc. | 18.55 Million USD | -2331.229% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -464.129% |
| Cingulate Inc. | 22.75 Million USD | -1881.586% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 6119.661% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -909.678% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -5377.244% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -339.744% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 40.193% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -626.541% |
| Clearmind Medicine Inc. | 8.74 Million USD | -5059.306% |
| Kronos Bio, Inc. | 128.11 Million USD | -252.014% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -436.437% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -15276.587% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -347.294% |
| Statera Biopharma, Inc. | 28.82 Million USD | -1464.345% |
| ImmunityBio, Inc. | 362.87 Million USD | -24.284% |
| Korro Bio, Inc. | 84.53 Million USD | -433.505% |
| Kineta, Inc. | 21.15 Million USD | -2031.75% |
| BioVie Inc. | 31.95 Million USD | -1311.549% |
| Codexis, Inc. | 66.51 Million USD | -578.001% |
| Celularity Inc. | 215.05 Million USD | -109.708% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -99.008% |
| Celcuity Inc. | 66.23 Million USD | -580.946% |
| Virax Biolabs Group Limited | 6.54 Million USD | -6788.478% |
| Cibus, Inc. | 320.3 Million USD | -40.801% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -948.821% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -1232.564% |
| IN8bio, Inc. | 30.33 Million USD | -1386.61% |
| Kodiak Sciences Inc. | 277.32 Million USD | -62.625% |
| Annexon, Inc. | 143.72 Million USD | -213.793% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -253.468% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -1868.628% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -70367.656% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 42.15% |
| Eyenovia, Inc. | 25.4 Million USD | -1675.113% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -221.415% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -8008.468% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -469.918% |
| Arcellx, Inc. | 200.19 Million USD | -125.272% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -882.556% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -108.397% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -4429.406% |
| Moolec Science SA | 52.75 Million USD | -754.953% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -637.664% |
| Geron Corporation | 70.44 Million USD | -540.242% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -869.044% |
| Royalty Pharma plc | 862.4 Million USD | 47.705% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -379.413% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -4734.9% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -1893.028% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -117.02% |
| Humacyte, Inc. | 23.49 Million USD | -1819.364% |
| Structure Therapeutics Inc. | 102.77 Million USD | -338.816% |
| 89bio, Inc. | 151.2 Million USD | -198.268% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -462.813% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -3001.74% |
| Genelux Corporation | 24.33 Million USD | -1753.269% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -1229.461% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -160.887% |
| Notable Labs, Ltd. | 14.77 Million USD | -2953.439% |
| Liquidia Corporation | 87.98 Million USD | -412.585% |
| Mustang Bio, Inc. | 48.5 Million USD | -829.863% |
| Immunovant, Inc. | 282.7 Million USD | -59.526% |
| Quantum-Si incorporated | 111.65 Million USD | -303.902% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -1900.501% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -2020.624% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -342.098% |
| Acasti Pharma Inc. | 11.3 Million USD | -3890.735% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -1867.588% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -2722.347% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -869.002% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -39649.775% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -2738.934% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -1446.774% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -989.776% |
| PepGen Inc. | 84.76 Million USD | -432.045% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -1422.031% |
| United Therapeutics Corporation | 885.1 Million USD | 49.046% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -1869.66% |
| Solid Biosciences Inc. | 104.31 Million USD | -332.338% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -1278.107% |
| Immuneering Corporation | 58.41 Million USD | -672.078% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -8759.962% |
| Silo Pharma, Inc. | 3.92 Million USD | -11399.479% |
| Belite Bio, Inc | 31.66 Million USD | -1324.128% |
| XOMA Corporation | 46.46 Million USD | -870.65% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -567.643% |
| Bionomics Limited | 17.89 Billion USD | 97.479% |
| Apogee Therapeutics, Inc. | 93 Million USD | -384.923% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1363.994% |
| uniQure N.V. | 285.08 Million USD | -58.195% |
| Cassava Sciences, Inc. | 105.95 Million USD | -325.638% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -6069.452% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -132.223% |
| Forte Biosciences, Inc. | 32.47 Million USD | -1288.654% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -5327.925% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -1434.251% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -8008.468% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -3073.772% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -4973.608% |
| Altimmune, Inc. | 30.55 Million USD | -1375.956% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -5.458% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 1363.994% |
| Compugen Ltd. | 43.97 Million USD | -925.66% |
| Peak Bio, Inc. | 1249.13 USD | -36104468.78% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -508.463% |
| Benitec Biopharma Inc. | 22.38 Million USD | -1914.981% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -85.45% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -1480.048% |
| Zura Bio Limited | 62.63 Million USD | -619.999% |
| PolyPid Ltd. | 21.04 Million USD | -2042.994% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -2670.908% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -1480.048% |
| Instil Bio, Inc. | 85.78 Million USD | -425.725% |
| argenx SE | 1.53 Billion USD | 70.591% |
| Immunome, Inc. | 122.82 Million USD | -267.198% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -830.4% |
| Verona Pharma plc | 67.15 Million USD | -571.607% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -1642.295% |
| Shattuck Labs, Inc. | 93.61 Million USD | -381.758% |
| CervoMed Inc. | 14.95 Million USD | -2915.109% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -537.87% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -5178.476% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -784.3% |
| Moolec Science SA | 52.75 Million USD | -754.953% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -2641.859% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -240.231% |
| AnaptysBio, Inc. | 181.56 Million USD | -148.388% |
| Design Therapeutics, Inc. | 78.19 Million USD | -476.791% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -418.139% |
| NeurAxis, Inc. | 8.82 Million USD | -5012.604% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -3483.576% |
| Lumos Pharma, Inc. | 38.66 Million USD | -1066.411% |
| Achilles Therapeutics plc | 75.25 Million USD | -499.286% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -1642.295% |
| 180 Life Sciences Corp. | 13.47 Million USD | -3246.266% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -1601.704% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -15276.587% |
| Nutriband Inc. | 5.73 Million USD | -7765.2% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -307.107% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -710.366% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -786.403% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -582.299% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -733.273% |
| Palisade Bio, Inc. | 13.32 Million USD | -3285.833% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -893.18% |
| Beam Therapeutics Inc. | 554.19 Million USD | 18.622% |
| Neurogene Inc. | 55.58 Million USD | -711.387% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -81.494% |
| AEON Biopharma, Inc. | 48.42 Million USD | -831.246% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -366.335% |
| Sesen Bio, Inc. | 78.38 Million USD | -475.386% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -439.924% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -3483.036% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -413.133% |
| Athira Pharma, Inc. | 125.46 Million USD | -259.454% |
| Vaccinex, Inc. | 23.45 Million USD | -1822.801% |
| HCW Biologics Inc. | 21.02 Million USD | -2044.775% |
| XOMA Corporation | 46.46 Million USD | -870.65% |
| Nektar Therapeutics | 190.9 Million USD | -136.242% |
| Arvinas, Inc. | 480 Million USD | 6.043% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -19732.847% |
| Merus N.V. | 200.49 Million USD | -124.941% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -336.353% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -1202.695% |
| Rezolute, Inc. | 70.38 Million USD | -540.733% |
| Clene Inc. | 41.07 Million USD | -998.028% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -2653.572% |
| BeyondSpring Inc. | 24.86 Million USD | -1713.766% |
| Synlogic, Inc. | 58.53 Million USD | -670.507% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -2420.641% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -9939.915% |
| Peak Bio, Inc. | 1249.13 USD | -36104468.78% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -646.109% |
| Krystal Biotech, Inc. | 160.42 Million USD | -181.122% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -66.645% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -29.582% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -20810.924% |
| MannKind Corporation | 125.59 Million USD | -259.079% |
| Ikena Oncology, Inc. | 84.57 Million USD | -433.234% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -4574.956% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -403.335% |
| Gossamer Bio, Inc. | 183.75 Million USD | -145.426% |
| CohBar, Inc. | 12.38 Million USD | -3540.476% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -789.112% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -1535.099% |
| Legend Biotech Corporation | 583.14 Million USD | 22.662% |
| Mural Oncology plc | 192.07 Million USD | -134.805% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -571.65% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -2693.344% |
| Disc Medicine, Inc. | 91.12 Million USD | -394.917% |
| Champions Oncology, Inc. | 28.11 Million USD | -1504.386% |
| REGENXBIO Inc. | 321.15 Million USD | -40.428% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -8312.112% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -708.869% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -1057.56% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -294.373% |
| Vaxart, Inc. | 90.72 Million USD | -397.093% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -5193.34% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -953.868% |
| Cellectis S.A. | 97.32 Million USD | -363.412% |
| Longeveron Inc. | 21.25 Million USD | -2022.32% |
| Repare Therapeutics Inc. | 167.35 Million USD | -169.48% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 66.859% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -496.197% |
| Revolution Medicines, Inc. | 498.76 Million USD | 9.578% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -6679.811% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -926.057% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -504.629% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -547.653% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -3977.694% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 90.555% |
| Denali Therapeutics Inc. | 527.23 Million USD | 14.46% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -5109.778% |
| Veru Inc. | 101.34 Million USD | -344.994% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -1826.744% |
| Cingulate Inc. | 22.75 Million USD | -1881.586% |
| Passage Bio, Inc. | 108.38 Million USD | -316.087% |
| Context Therapeutics Inc. | 25.07 Million USD | -1698.747% |
| Exicure, Inc. | 14.07 Million USD | -3103.986% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -118.861% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -941.53% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -4814.228% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -78.623% |
| Nuvalent, Inc. | 149.49 Million USD | -201.684% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -5490.659% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -335.111% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -2002.629% |
| OmniAb, Inc. | 83.89 Million USD | -437.568% |
| Anew Medical, Inc. | 1.3 Million USD | -34569.341% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -1276.489% |
| Lipocine Inc. | 15.08 Million USD | -2890.642% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -558.259% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -492.227% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -1018.692% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -292.704% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -1914.801% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 32.094% |
| Ocugen, Inc. | 71.56 Million USD | -530.169% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -380.465% |
| Q32 Bio Inc. | 92.68 Million USD | -386.613% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -2029.938% |
| Alumis Inc. Common Stock | 158.17 Million USD | -185.125% |
| Equillium, Inc. | 50.6 Million USD | -791.185% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -622.676% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -3143.258% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -2290.62% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -860.561% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -315.792% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -3539.175% |
| Dominari Holdings Inc. | 23.83 Million USD | -1792.146% |
| Edesa Biotech, Inc. | 9.22 Million USD | -4790.001% |
| vTv Therapeutics Inc. | 11.9 Million USD | -3687.629% |
| Bio-Techne Corporation | 563.03 Million USD | 19.9% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -10.32% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -67.808% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -240.946% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -3029.505% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -175.506% |
| Nkarta, Inc. | 131.65 Million USD | -242.57% |
| BioCardia, Inc. | 12.12 Million USD | -3620.757% |
| Iterum Therapeutics plc | 47.46 Million USD | -850.099% |